ALK/EGFR-IN-1-d5 

ALK/EGFR-IN-1-d5 (Compound (-)-9a) is a deuterated dual-target inhibitor of EGFR and ALK, with an IC₅₀ of 1.08 nM for EGFR and an IC₅₀ of 2.395 nM for ALK. ALK/EGFR-IN-1-d5 inhibits the phosphorylated proteins in the EGFR, ALK, and BRK signaling pathways, blocking the cell cycle, leading to a reduction in mitochondrial membrane potential and cell apoptosis (Apoptosis). ALK/EGFR-IN-1-d5 also significantly inhibits tumor growth in animal models and demonstrates good safety. ALK/EGFR-IN-1-d5 holds promise for research in the field of cancer treatment^[1]

577.15

C₂₇H₂₉D₅ClN₇O₃S

2730429-93-1

CN(C)CCN(C1=C(C=C(C(OC)=C1)NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(C([2H])([2H])C([2H])([2H])[2H])=O)=N2)NC(C=C)=O)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Nie H, et al. Synthesis of novel deuterated EGFR/ALK dual-target inhibitors and their activity against non-small cell lung cancer. Eur J Med Chem. 2025 Feb 5;283:117146.  [Content Brief]